Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Detection of allo- or autoantibodies directed against red blood cell antigens in the settings of pretransfusion testing
Evaluation of transfusion reactions
Evaluation of hemolytic anemia
If the antibody screen is positive, then antibody identification will be performed.
If the patient has a history of antibodies that are still detected, the antibody screen will be canceled and replaced by the antibody identification.
If certain antibodies are detected and the patient is known to be pregnant, an antibody titration will be performed.
Transfusion and pregnancy are the primary means of sensitization to red cell antigens. In a given population, 2% to 4% of the general population possess irregular red cell alloantibodies. Such antibodies may cause hemolytic disease of the newborn or hemolysis of transfused donor red blood cells.
Negative
If positive, antibody identification will be performed.
A positive result (antibody detected) necessitates antibody identification to establish the specificity and clinical significance of the antibody detected.
Alloantibodies detected on pregnant Mayo Clinic-Rochester patients will be evaluated for the allo-antibody titer. If antibody reacts strongly, the titre test will be performed.
Negative results indicate no antibody was detected.
Clinical evaluation of antibodies identified is necessary to determine their potential for harm to the patient at this time and to assess appropriate action to be taken in the future.
AABB Technical Manual. 19th edition. Edited by MK Fung, AF Eder, SL Spitalnik, CM Westhoff: AABB 2017